Pharmacological characterization of alpha1-adrenoceptors in equine digital veins.

This article examines how alpha1-adrenoceptors, which mediate contractile responses in horse veins of the foot (EDVs), function. The research is particularly focused on one subtype of these receptors as it holds potential for treating acute laminitis, a common and severe equine condition.

Focus of the Study

• The study revolves around alpha-adrenoceptors, which contribute to muscle contractions in the veins found in horses’ hooves.
• The researchers chose to concentrate their investigation on these receptors in the veins as the veins have been implicated specifically in acute laminitis. This is significant as it may provide insight into treating the condition.

Methods

• The study used isolated rings of equine digital veins (EDVs) and recorded their contractile responses under conditions of isometric tension.
• The researchers measured the potency of several specific alpha-adrenoceptor selective agonists and antagonists.
• Agonists are substances that increase the action of a process, while antagonists reduce this action.

Results

• The results indicated that A61603 was the most potent agonist, showing a 76-fold greater potency than another agonist, phenylephrine. This suggests the presence of the alpha(1A)-adrenoceptor subtype.
• The drug prazosin caused a competitive inhibition of their responses, meaning it decreased their effects.
• Another antagonist, WB4101, also decreased the responses to the agonists, confirming the presence of the alpha(1A)-adrenoceptor subtype.
• BMY7378, an antagonist selective for another subtype, the alpha1D-adrenoceptor, failed to cause significant changes.
• An antagonist called chloroethylclonidine dihydrochloride was used specifically to deactivate the alpha(1B)-adrenoceptors. However, it only inhibited the response to phenylephrine, not A61603. This finding indicates the existence of two distinct alpha(1)-adrenoceptor groups, principally of the alpha(1A) and alpha(1B) subtypes.

Implications

• These findings can contribute to the development of more selective, effective antagonists to counter alpha1A and alpha1B adrenoceptors. In turn, this could lead to new therapeutic interventions in horses for conditions like acute laminitis.